Literature DB >> 3285774

Selective manipulation of the immune response in vivo by monoclonal antibodies.

W E Seaman1, D Wofsy.   

Abstract

The development of monoclonal antilymphocyte antibodies has greatly enhanced our ability to identify and bind specific antigens selectively on functionally distinct cells of the immune system. As a result, monoclonal antibodies have become a valuable tool in studies of the cellular mechanisms underlying immune responses. Moreover, because they can selectively alter immune responses in vivo, monoclonal antilymphocyte antibodies hold considerable promise as potential therapeutic agents for immunologically mediated disorders such as allograft rejection, graft-vs-host disease, and many autoimmune diseases. This review addresses the prospects for using monoclonal antilymphocyte antibodies in vivo and discusses some of the problems that remain to be solved.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3285774     DOI: 10.1146/annurev.me.39.020188.001311

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  4 in total

1.  Requirement of CD4-positive T cells for cellular recruitment to the lungs of mice in response to a particulate intratracheal antigen.

Authors:  J L Curtis; P K Byrd; M L Warnock; H B Kaltreider
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

Review 2.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

3.  Elimination of CD4+ suppressor T cells from susceptible BALB/c mice releases CD8+ T lymphocytes to mediate protective immunity against Leishmania.

Authors:  J O Hill; M Awwad; R J North
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

4.  Induction of peripheral tolerance to class I major histocompatibility complex (MHC) alloantigens in adult mice: transfused class I MHC-incompatible splenocytes veto clonal responses of antigen-reactive Lyt-2+ T cells.

Authors:  K Heeg; H Wagner
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.